nodes	percent_of_prediction	percent_of_DWPC	metapath
Linezolid—Aspartate aminotransferase increased—Vincristine—lymphatic system cancer	0.00256	0.00256	CcSEcCtD
Linezolid—Thrombocytopenia—Teniposide—lymphatic system cancer	0.00255	0.00255	CcSEcCtD
Linezolid—Hypokalaemia—Mitoxantrone—lymphatic system cancer	0.00252	0.00252	CcSEcCtD
Linezolid—Hyperhidrosis—Teniposide—lymphatic system cancer	0.00251	0.00251	CcSEcCtD
Linezolid—Leukopenia—Fludarabine—lymphatic system cancer	0.00251	0.00251	CcSEcCtD
Linezolid—Pruritus—Mechlorethamine—lymphatic system cancer	0.0025	0.0025	CcSEcCtD
Linezolid—Aspartate aminotransferase increased—Mitoxantrone—lymphatic system cancer	0.00249	0.00249	CcSEcCtD
Linezolid—Anorexia—Teniposide—lymphatic system cancer	0.00248	0.00248	CcSEcCtD
Linezolid—Fungal infection—Methotrexate—lymphatic system cancer	0.00246	0.00246	CcSEcCtD
Linezolid—Cough—Fludarabine—lymphatic system cancer	0.00244	0.00244	CcSEcCtD
Linezolid—Pancytopenia—Carmustine—lymphatic system cancer	0.00244	0.00244	CcSEcCtD
Linezolid—Alanine aminotransferase increased—Mitoxantrone—lymphatic system cancer	0.00244	0.00244	CcSEcCtD
Linezolid—Skin ulcer—Methotrexate—lymphatic system cancer	0.00244	0.00244	CcSEcCtD
Linezolid—Convulsion—Fludarabine—lymphatic system cancer	0.00243	0.00243	CcSEcCtD
Linezolid—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.00241	0.00241	CcSEcCtD
Linezolid—Neutropenia—Carmustine—lymphatic system cancer	0.00241	0.00241	CcSEcCtD
Linezolid—Haemoglobin—Bleomycin—lymphatic system cancer	0.00237	0.00237	CcSEcCtD
Linezolid—Haemorrhage—Bleomycin—lymphatic system cancer	0.00236	0.00236	CcSEcCtD
Linezolid—Hypoaesthesia—Bleomycin—lymphatic system cancer	0.00235	0.00235	CcSEcCtD
Linezolid—Pancytopenia—Vincristine—lymphatic system cancer	0.00233	0.00233	CcSEcCtD
Linezolid—Sweating increased—Mitoxantrone—lymphatic system cancer	0.00233	0.00233	CcSEcCtD
Linezolid—Hyperglycaemia—Carmustine—lymphatic system cancer	0.00232	0.00232	CcSEcCtD
Linezolid—Dyspnoea—Teniposide—lymphatic system cancer	0.00232	0.00232	CcSEcCtD
Linezolid—Pneumonia—Carmustine—lymphatic system cancer	0.00231	0.00231	CcSEcCtD
Linezolid—Neutropenia—Vincristine—lymphatic system cancer	0.0023	0.0023	CcSEcCtD
Linezolid—Anaphylactic shock—Fludarabine—lymphatic system cancer	0.00229	0.00229	CcSEcCtD
Linezolid—Pancytopenia—Mitoxantrone—lymphatic system cancer	0.00227	0.00227	CcSEcCtD
Linezolid—Decreased appetite—Teniposide—lymphatic system cancer	0.00226	0.00226	CcSEcCtD
Linezolid—Renal failure—Carmustine—lymphatic system cancer	0.00226	0.00226	CcSEcCtD
Linezolid—Neuropathy peripheral—Carmustine—lymphatic system cancer	0.00225	0.00225	CcSEcCtD
Linezolid—Vomiting—Mechlorethamine—lymphatic system cancer	0.00224	0.00224	CcSEcCtD
Linezolid—Apnoea—Methotrexate—lymphatic system cancer	0.00224	0.00224	CcSEcCtD
Linezolid—Thrombocytopenia—Fludarabine—lymphatic system cancer	0.00224	0.00224	CcSEcCtD
Linezolid—Neutropenia—Mitoxantrone—lymphatic system cancer	0.00224	0.00224	CcSEcCtD
Linezolid—Stomatitis—Carmustine—lymphatic system cancer	0.00224	0.00224	CcSEcCtD
Linezolid—Rash—Mechlorethamine—lymphatic system cancer	0.00222	0.00222	CcSEcCtD
Linezolid—Upper respiratory tract infection—Mitoxantrone—lymphatic system cancer	0.00222	0.00222	CcSEcCtD
Linezolid—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00222	0.00222	CcSEcCtD
Linezolid—Hyperhidrosis—Fludarabine—lymphatic system cancer	0.00221	0.00221	CcSEcCtD
Linezolid—Pneumonia—Vincristine—lymphatic system cancer	0.0022	0.0022	CcSEcCtD
Linezolid—Anorexia—Fludarabine—lymphatic system cancer	0.00218	0.00218	CcSEcCtD
Linezolid—Hyperglycaemia—Mitoxantrone—lymphatic system cancer	0.00216	0.00216	CcSEcCtD
Linezolid—Neuropathy peripheral—Vincristine—lymphatic system cancer	0.00215	0.00215	CcSEcCtD
Linezolid—Pneumonia—Mitoxantrone—lymphatic system cancer	0.00215	0.00215	CcSEcCtD
Linezolid—Stomatitis—Vincristine—lymphatic system cancer	0.00213	0.00213	CcSEcCtD
Linezolid—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.00213	0.00213	CcSEcCtD
Linezolid—Chills—Bleomycin—lymphatic system cancer	0.00212	0.00212	CcSEcCtD
Linezolid—Renal failure—Mitoxantrone—lymphatic system cancer	0.0021	0.0021	CcSEcCtD
Linezolid—Nausea—Mechlorethamine—lymphatic system cancer	0.0021	0.0021	CcSEcCtD
Linezolid—Stomatitis—Mitoxantrone—lymphatic system cancer	0.00208	0.00208	CcSEcCtD
Linezolid—Haemoglobin—Carmustine—lymphatic system cancer	0.00207	0.00207	CcSEcCtD
Linezolid—Urticaria—Teniposide—lymphatic system cancer	0.00207	0.00207	CcSEcCtD
Linezolid—Glossitis—Methotrexate—lymphatic system cancer	0.00206	0.00206	CcSEcCtD
Linezolid—Haemorrhage—Carmustine—lymphatic system cancer	0.00206	0.00206	CcSEcCtD
Linezolid—Abdominal pain—Teniposide—lymphatic system cancer	0.00206	0.00206	CcSEcCtD
Linezolid—Body temperature increased—Teniposide—lymphatic system cancer	0.00206	0.00206	CcSEcCtD
Linezolid—Erythema—Bleomycin—lymphatic system cancer	0.00205	0.00205	CcSEcCtD
Linezolid—Paraesthesia—Fludarabine—lymphatic system cancer	0.00205	0.00205	CcSEcCtD
Linezolid—Hypoaesthesia—Carmustine—lymphatic system cancer	0.00205	0.00205	CcSEcCtD
Linezolid—Dyspnoea—Fludarabine—lymphatic system cancer	0.00204	0.00204	CcSEcCtD
Linezolid—Dyspepsia—Fludarabine—lymphatic system cancer	0.00201	0.00201	CcSEcCtD
Linezolid—Decreased appetite—Fludarabine—lymphatic system cancer	0.00199	0.00199	CcSEcCtD
Linezolid—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.00197	0.00197	CcSEcCtD
Linezolid—Fatigue—Fludarabine—lymphatic system cancer	0.00197	0.00197	CcSEcCtD
Linezolid—Hypoaesthesia—Vincristine—lymphatic system cancer	0.00196	0.00196	CcSEcCtD
Linezolid—Pain—Fludarabine—lymphatic system cancer	0.00196	0.00196	CcSEcCtD
Linezolid—Constipation—Fludarabine—lymphatic system cancer	0.00196	0.00196	CcSEcCtD
Linezolid—Haemoglobin—Mitoxantrone—lymphatic system cancer	0.00192	0.00192	CcSEcCtD
Linezolid—Haemorrhage—Mitoxantrone—lymphatic system cancer	0.00191	0.00191	CcSEcCtD
Linezolid—Pharyngitis—Mitoxantrone—lymphatic system cancer	0.0019	0.0019	CcSEcCtD
Linezolid—Vaginal inflammation—Methotrexate—lymphatic system cancer	0.0019	0.0019	CcSEcCtD
Linezolid—Anaemia—Bleomycin—lymphatic system cancer	0.0019	0.0019	CcSEcCtD
Linezolid—Asthenia—Teniposide—lymphatic system cancer	0.00187	0.00187	CcSEcCtD
Linezolid—Pruritus—Teniposide—lymphatic system cancer	0.00184	0.00184	CcSEcCtD
Linezolid—Leukopenia—Bleomycin—lymphatic system cancer	0.00184	0.00184	CcSEcCtD
Linezolid—Body temperature increased—Fludarabine—lymphatic system cancer	0.00181	0.00181	CcSEcCtD
Linezolid—Vaginal infection—Methotrexate—lymphatic system cancer	0.00179	0.00179	CcSEcCtD
Linezolid—Erythema—Carmustine—lymphatic system cancer	0.00179	0.00179	CcSEcCtD
Linezolid—Cough—Bleomycin—lymphatic system cancer	0.00179	0.00179	CcSEcCtD
Linezolid—Diarrhoea—Teniposide—lymphatic system cancer	0.00178	0.00178	CcSEcCtD
Linezolid—Chills—Mitoxantrone—lymphatic system cancer	0.00172	0.00172	CcSEcCtD
Linezolid—Ecchymosis—Methotrexate—lymphatic system cancer	0.00172	0.00172	CcSEcCtD
Linezolid—Urine output increased—Methotrexate—lymphatic system cancer	0.00172	0.00172	CcSEcCtD
Linezolid—Vision blurred—Carmustine—lymphatic system cancer	0.00169	0.00169	CcSEcCtD
Linezolid—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.00168	0.00168	CcSEcCtD
Linezolid—Erythema—Mitoxantrone—lymphatic system cancer	0.00167	0.00167	CcSEcCtD
Linezolid—Anaemia—Carmustine—lymphatic system cancer	0.00166	0.00166	CcSEcCtD
Linezolid—Vomiting—Teniposide—lymphatic system cancer	0.00165	0.00165	CcSEcCtD
Linezolid—Sepsis—Methotrexate—lymphatic system cancer	0.00165	0.00165	CcSEcCtD
Linezolid—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.00164	0.00164	CcSEcCtD
Linezolid—Asthenia—Fludarabine—lymphatic system cancer	0.00164	0.00164	CcSEcCtD
Linezolid—Rash—Teniposide—lymphatic system cancer	0.00164	0.00164	CcSEcCtD
Linezolid—Dermatitis—Teniposide—lymphatic system cancer	0.00164	0.00164	CcSEcCtD
Linezolid—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.00163	0.00163	CcSEcCtD
Linezolid—Headache—Teniposide—lymphatic system cancer	0.00163	0.00163	CcSEcCtD
Linezolid—Pruritus—Fludarabine—lymphatic system cancer	0.00162	0.00162	CcSEcCtD
Linezolid—Leukopenia—Carmustine—lymphatic system cancer	0.0016	0.0016	CcSEcCtD
Linezolid—Anorexia—Bleomycin—lymphatic system cancer	0.0016	0.0016	CcSEcCtD
Linezolid—Thrombophlebitis—Methotrexate—lymphatic system cancer	0.00159	0.00159	CcSEcCtD
Linezolid—Anaemia—Vincristine—lymphatic system cancer	0.00158	0.00158	CcSEcCtD
Linezolid—Vision blurred—Mitoxantrone—lymphatic system cancer	0.00157	0.00157	CcSEcCtD
Linezolid—Polyuria—Methotrexate—lymphatic system cancer	0.00157	0.00157	CcSEcCtD
Linezolid—Diarrhoea—Fludarabine—lymphatic system cancer	0.00156	0.00156	CcSEcCtD
Linezolid—Convulsion—Carmustine—lymphatic system cancer	0.00155	0.00155	CcSEcCtD
Linezolid—Hypertension—Carmustine—lymphatic system cancer	0.00155	0.00155	CcSEcCtD
Linezolid—Nausea—Teniposide—lymphatic system cancer	0.00155	0.00155	CcSEcCtD
Linezolid—Anaemia—Mitoxantrone—lymphatic system cancer	0.00154	0.00154	CcSEcCtD
Linezolid—Vertigo—Vincristine—lymphatic system cancer	0.00154	0.00154	CcSEcCtD
Linezolid—Leukopenia—Vincristine—lymphatic system cancer	0.00153	0.00153	CcSEcCtD
Linezolid—Paraesthesia—Bleomycin—lymphatic system cancer	0.00151	0.00151	CcSEcCtD
Linezolid—Dyspnoea—Bleomycin—lymphatic system cancer	0.00149	0.00149	CcSEcCtD
Linezolid—Leukopenia—Mitoxantrone—lymphatic system cancer	0.00149	0.00149	CcSEcCtD
Linezolid—Convulsion—Vincristine—lymphatic system cancer	0.00148	0.00148	CcSEcCtD
Linezolid—Hypertension—Vincristine—lymphatic system cancer	0.00148	0.00148	CcSEcCtD
Linezolid—Decreased appetite—Bleomycin—lymphatic system cancer	0.00146	0.00146	CcSEcCtD
Linezolid—Cough—Mitoxantrone—lymphatic system cancer	0.00145	0.00145	CcSEcCtD
Linezolid—Vomiting—Fludarabine—lymphatic system cancer	0.00145	0.00145	CcSEcCtD
Linezolid—Convulsion—Mitoxantrone—lymphatic system cancer	0.00144	0.00144	CcSEcCtD
Linezolid—Rash—Fludarabine—lymphatic system cancer	0.00144	0.00144	CcSEcCtD
Linezolid—Dermatitis—Fludarabine—lymphatic system cancer	0.00144	0.00144	CcSEcCtD
Linezolid—Hypertension—Mitoxantrone—lymphatic system cancer	0.00144	0.00144	CcSEcCtD
Linezolid—Pain—Bleomycin—lymphatic system cancer	0.00143	0.00143	CcSEcCtD
Linezolid—Thrombocytopenia—Carmustine—lymphatic system cancer	0.00143	0.00143	CcSEcCtD
Linezolid—Headache—Fludarabine—lymphatic system cancer	0.00143	0.00143	CcSEcCtD
Linezolid—Anaphylactic shock—Vincristine—lymphatic system cancer	0.0014	0.0014	CcSEcCtD
Linezolid—Anorexia—Carmustine—lymphatic system cancer	0.00139	0.00139	CcSEcCtD
Linezolid—Thrombocytopenia—Vincristine—lymphatic system cancer	0.00137	0.00137	CcSEcCtD
Linezolid—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.00136	0.00136	CcSEcCtD
Linezolid—Nausea—Fludarabine—lymphatic system cancer	0.00136	0.00136	CcSEcCtD
Linezolid—Hyperhidrosis—Vincristine—lymphatic system cancer	0.00135	0.00135	CcSEcCtD
Linezolid—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.00133	0.00133	CcSEcCtD
Linezolid—Urticaria—Bleomycin—lymphatic system cancer	0.00133	0.00133	CcSEcCtD
Linezolid—Anorexia—Vincristine—lymphatic system cancer	0.00133	0.00133	CcSEcCtD
Linezolid—Body temperature increased—Bleomycin—lymphatic system cancer	0.00133	0.00133	CcSEcCtD
Linezolid—Insomnia—Carmustine—lymphatic system cancer	0.00132	0.00132	CcSEcCtD
Linezolid—Skin disorder—Mitoxantrone—lymphatic system cancer	0.00132	0.00132	CcSEcCtD
Linezolid—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.00131	0.00131	CcSEcCtD
Linezolid—Paraesthesia—Carmustine—lymphatic system cancer	0.00131	0.00131	CcSEcCtD
Linezolid—Dyspnoea—Carmustine—lymphatic system cancer	0.0013	0.0013	CcSEcCtD
Linezolid—Somnolence—Carmustine—lymphatic system cancer	0.0013	0.0013	CcSEcCtD
Linezolid—Anorexia—Mitoxantrone—lymphatic system cancer	0.0013	0.0013	CcSEcCtD
Linezolid—Liver function test abnormal—Methotrexate—lymphatic system cancer	0.00127	0.00127	CcSEcCtD
Linezolid—Decreased appetite—Carmustine—lymphatic system cancer	0.00127	0.00127	CcSEcCtD
Linezolid—Insomnia—Vincristine—lymphatic system cancer	0.00126	0.00126	CcSEcCtD
Linezolid—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.00126	0.00126	CcSEcCtD
Linezolid—Paraesthesia—Vincristine—lymphatic system cancer	0.00125	0.00125	CcSEcCtD
Linezolid—Pain—Carmustine—lymphatic system cancer	0.00125	0.00125	CcSEcCtD
Linezolid—Constipation—Carmustine—lymphatic system cancer	0.00125	0.00125	CcSEcCtD
Linezolid—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.00122	0.00122	CcSEcCtD
Linezolid—Decreased appetite—Vincristine—lymphatic system cancer	0.00121	0.00121	CcSEcCtD
Linezolid—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.00121	0.00121	CcSEcCtD
Linezolid—Somnolence—Mitoxantrone—lymphatic system cancer	0.00121	0.00121	CcSEcCtD
Linezolid—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.00121	0.00121	CcSEcCtD
Linezolid—Fatigue—Vincristine—lymphatic system cancer	0.0012	0.0012	CcSEcCtD
Linezolid—Asthenia—Bleomycin—lymphatic system cancer	0.0012	0.0012	CcSEcCtD
Linezolid—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.0012	0.0012	CcSEcCtD
Linezolid—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.0012	0.0012	CcSEcCtD
Linezolid—Pain—Vincristine—lymphatic system cancer	0.00119	0.00119	CcSEcCtD
Linezolid—Constipation—Vincristine—lymphatic system cancer	0.00119	0.00119	CcSEcCtD
Linezolid—Pruritus—Bleomycin—lymphatic system cancer	0.00119	0.00119	CcSEcCtD
Linezolid—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.00118	0.00118	CcSEcCtD
Linezolid—Eosinophilia—Methotrexate—lymphatic system cancer	0.00118	0.00118	CcSEcCtD
Linezolid—Fatigue—Mitoxantrone—lymphatic system cancer	0.00117	0.00117	CcSEcCtD
Linezolid—Pancreatitis—Methotrexate—lymphatic system cancer	0.00117	0.00117	CcSEcCtD
Linezolid—Pain—Mitoxantrone—lymphatic system cancer	0.00116	0.00116	CcSEcCtD
Linezolid—Constipation—Mitoxantrone—lymphatic system cancer	0.00116	0.00116	CcSEcCtD
Linezolid—Body temperature increased—Carmustine—lymphatic system cancer	0.00116	0.00116	CcSEcCtD
Linezolid—Abdominal pain—Carmustine—lymphatic system cancer	0.00116	0.00116	CcSEcCtD
Linezolid—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.00114	0.00114	CcSEcCtD
Linezolid—Pancytopenia—Methotrexate—lymphatic system cancer	0.00113	0.00113	CcSEcCtD
Linezolid—Neutropenia—Methotrexate—lymphatic system cancer	0.00111	0.00111	CcSEcCtD
Linezolid—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.00111	0.00111	CcSEcCtD
Linezolid—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	0.00111	0.00111	CcSEcCtD
Linezolid—Abdominal pain—Vincristine—lymphatic system cancer	0.0011	0.0011	CcSEcCtD
Linezolid—Body temperature increased—Vincristine—lymphatic system cancer	0.0011	0.0011	CcSEcCtD
Linezolid—Urticaria—Mitoxantrone—lymphatic system cancer	0.00108	0.00108	CcSEcCtD
Linezolid—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.00108	0.00108	CcSEcCtD
Linezolid—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.00108	0.00108	CcSEcCtD
Linezolid—Pneumonia—Methotrexate—lymphatic system cancer	0.00107	0.00107	CcSEcCtD
Linezolid—Vomiting—Bleomycin—lymphatic system cancer	0.00107	0.00107	CcSEcCtD
Linezolid—Rash—Bleomycin—lymphatic system cancer	0.00106	0.00106	CcSEcCtD
Linezolid—Dermatitis—Bleomycin—lymphatic system cancer	0.00106	0.00106	CcSEcCtD
Linezolid—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	0.00105	0.00105	CcSEcCtD
Linezolid—Asthenia—Carmustine—lymphatic system cancer	0.00105	0.00105	CcSEcCtD
Linezolid—Renal failure—Methotrexate—lymphatic system cancer	0.00104	0.00104	CcSEcCtD
Linezolid—Stomatitis—Methotrexate—lymphatic system cancer	0.00104	0.00104	CcSEcCtD
Linezolid—Asthenia—Vincristine—lymphatic system cancer	0.001	0.001	CcSEcCtD
Linezolid—Diarrhoea—Carmustine—lymphatic system cancer	0.001	0.001	CcSEcCtD
Linezolid—Nausea—Bleomycin—lymphatic system cancer	0.000996	0.000996	CcSEcCtD
Linezolid—Asthenia—Mitoxantrone—lymphatic system cancer	0.000976	0.000976	CcSEcCtD
Linezolid—Dizziness—Carmustine—lymphatic system cancer	0.000968	0.000968	CcSEcCtD
Linezolid—Haemoglobin—Methotrexate—lymphatic system cancer	0.000959	0.000959	CcSEcCtD
Linezolid—Diarrhoea—Vincristine—lymphatic system cancer	0.000956	0.000956	CcSEcCtD
Linezolid—Haemorrhage—Methotrexate—lymphatic system cancer	0.000954	0.000954	CcSEcCtD
Linezolid—Pharyngitis—Methotrexate—lymphatic system cancer	0.000947	0.000947	CcSEcCtD
Linezolid—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000931	0.000931	CcSEcCtD
Linezolid—Vomiting—Carmustine—lymphatic system cancer	0.00093	0.00093	CcSEcCtD
Linezolid—Dizziness—Vincristine—lymphatic system cancer	0.000924	0.000924	CcSEcCtD
Linezolid—Rash—Carmustine—lymphatic system cancer	0.000923	0.000923	CcSEcCtD
Linezolid—Dermatitis—Carmustine—lymphatic system cancer	0.000922	0.000922	CcSEcCtD
Linezolid—Headache—Carmustine—lymphatic system cancer	0.000917	0.000917	CcSEcCtD
Linezolid—Erythema multiforme—Methotrexate—lymphatic system cancer	0.000902	0.000902	CcSEcCtD
Linezolid—Tinnitus—Methotrexate—lymphatic system cancer	0.000889	0.000889	CcSEcCtD
Linezolid—Vomiting—Vincristine—lymphatic system cancer	0.000888	0.000888	CcSEcCtD
Linezolid—Rash—Vincristine—lymphatic system cancer	0.000881	0.000881	CcSEcCtD
Linezolid—Dermatitis—Vincristine—lymphatic system cancer	0.00088	0.00088	CcSEcCtD
Linezolid—Headache—Vincristine—lymphatic system cancer	0.000875	0.000875	CcSEcCtD
Linezolid—Nausea—Carmustine—lymphatic system cancer	0.000869	0.000869	CcSEcCtD
Linezolid—Vomiting—Mitoxantrone—lymphatic system cancer	0.000865	0.000865	CcSEcCtD
Linezolid—Rash—Mitoxantrone—lymphatic system cancer	0.000858	0.000858	CcSEcCtD
Linezolid—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000857	0.000857	CcSEcCtD
Linezolid—Chills—Methotrexate—lymphatic system cancer	0.000856	0.000856	CcSEcCtD
Linezolid—Headache—Mitoxantrone—lymphatic system cancer	0.000852	0.000852	CcSEcCtD
Linezolid—Erythema—Methotrexate—lymphatic system cancer	0.00083	0.00083	CcSEcCtD
Linezolid—Nausea—Vincristine—lymphatic system cancer	0.00083	0.00083	CcSEcCtD
Linezolid—Dysgeusia—Methotrexate—lymphatic system cancer	0.000813	0.000813	CcSEcCtD
Linezolid—Nausea—Mitoxantrone—lymphatic system cancer	0.000808	0.000808	CcSEcCtD
Linezolid—Vision blurred—Methotrexate—lymphatic system cancer	0.000783	0.000783	CcSEcCtD
Linezolid—Anaemia—Methotrexate—lymphatic system cancer	0.000768	0.000768	CcSEcCtD
Linezolid—Vertigo—Methotrexate—lymphatic system cancer	0.000746	0.000746	CcSEcCtD
Linezolid—Leukopenia—Methotrexate—lymphatic system cancer	0.000743	0.000743	CcSEcCtD
Linezolid—Cough—Methotrexate—lymphatic system cancer	0.000725	0.000725	CcSEcCtD
Linezolid—Convulsion—Methotrexate—lymphatic system cancer	0.000719	0.000719	CcSEcCtD
Linezolid—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.000678	0.000678	CcSEcCtD
Linezolid—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000664	0.000664	CcSEcCtD
Linezolid—Skin disorder—Methotrexate—lymphatic system cancer	0.000658	0.000658	CcSEcCtD
Linezolid—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000655	0.000655	CcSEcCtD
Linezolid—Anorexia—Methotrexate—lymphatic system cancer	0.000646	0.000646	CcSEcCtD
Linezolid—Insomnia—Methotrexate—lymphatic system cancer	0.000613	0.000613	CcSEcCtD
Linezolid—Paraesthesia—Methotrexate—lymphatic system cancer	0.000609	0.000609	CcSEcCtD
Linezolid—Dyspnoea—Methotrexate—lymphatic system cancer	0.000604	0.000604	CcSEcCtD
Linezolid—Somnolence—Methotrexate—lymphatic system cancer	0.000603	0.000603	CcSEcCtD
Linezolid—Dyspepsia—Methotrexate—lymphatic system cancer	0.000597	0.000597	CcSEcCtD
Linezolid—Decreased appetite—Methotrexate—lymphatic system cancer	0.000589	0.000589	CcSEcCtD
Linezolid—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000585	0.000585	CcSEcCtD
Linezolid—Fatigue—Methotrexate—lymphatic system cancer	0.000584	0.000584	CcSEcCtD
Linezolid—Pain—Methotrexate—lymphatic system cancer	0.00058	0.00058	CcSEcCtD
Linezolid—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000554	0.000554	CcSEcCtD
Linezolid—Urticaria—Methotrexate—lymphatic system cancer	0.000538	0.000538	CcSEcCtD
Linezolid—Body temperature increased—Methotrexate—lymphatic system cancer	0.000536	0.000536	CcSEcCtD
Linezolid—Abdominal pain—Methotrexate—lymphatic system cancer	0.000536	0.000536	CcSEcCtD
Linezolid—Asthenia—Methotrexate—lymphatic system cancer	0.000486	0.000486	CcSEcCtD
Linezolid—Pruritus—Methotrexate—lymphatic system cancer	0.000479	0.000479	CcSEcCtD
Linezolid—Diarrhoea—Methotrexate—lymphatic system cancer	0.000464	0.000464	CcSEcCtD
Linezolid—Dizziness—Methotrexate—lymphatic system cancer	0.000448	0.000448	CcSEcCtD
Linezolid—Vomiting—Methotrexate—lymphatic system cancer	0.000431	0.000431	CcSEcCtD
Linezolid—Rash—Methotrexate—lymphatic system cancer	0.000427	0.000427	CcSEcCtD
Linezolid—Dermatitis—Methotrexate—lymphatic system cancer	0.000427	0.000427	CcSEcCtD
Linezolid—Headache—Methotrexate—lymphatic system cancer	0.000425	0.000425	CcSEcCtD
Linezolid—Nausea—Methotrexate—lymphatic system cancer	0.000403	0.000403	CcSEcCtD
